Samarth Kulkarni Sells 9,798 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 9,798 shares of CRISPR Therapeutics stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $52.80, for a total transaction of $517,334.40. Following the completion of the sale, the chief executive officer owned 235,558 shares in the company, valued at approximately $12,437,462.40. This trade represents a 3.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Samarth Kulkarni also recently made the following trade(s):

• On Thursday, February 19th, Samarth Kulkarni sold 6,967 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $52.58, for a total transaction of $366,324.86.
• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total transaction of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Trading Down 0.2%

Shares of CRSP opened at $48.75 on Friday. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The firm’s 50-day moving average price is $54.10 and its 200-day moving average price is $57.24. The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of -7.48 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The company had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The business’s quarterly revenue was down 97.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.01) earnings per share. On average, research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on CRSP. Citizens Jmp dropped their price target on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research report on Friday, January 30th. TD Cowen increased their price objective on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Needham & Company LLC raised their price objective on CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, February 13th. Chardan Capital boosted their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a report on Saturday, February 14th. Finally, Bank of America reduced their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $64.24.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mcguire Capital Advisors Inc. bought a new stake in CRISPR Therapeutics in the fourth quarter worth $25,000. Ramirez Asset Management Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $26,000. Rothschild Investment LLC increased its holdings in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after acquiring an additional 502 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. raised its position in shares of CRISPR Therapeutics by 196.9% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after purchasing an additional 382 shares during the last quarter. Finally, Atlantic Union Bankshares Corp bought a new position in CRISPR Therapeutics in the 2nd quarter worth about $33,000. Institutional investors own 69.20% of the company’s stock.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: FY‑2025 commercial progress: management reported $116M in FY‑25 revenue driven by CASGEVY, including $54M in Q4, which supports the company’s early commercial trajectory and longer‑term revenue potential. Read More.
• Positive Sentiment: Institutional buying noted: coverage flagged that ARK Invest added CRSP stock, indicating renewed institutional interest that can provide buying support and liquidity. Read More.
• Positive Sentiment: Analyst estimate tweaks: Brookline Capital made small near‑term EPS adjustments (slightly less negative for FY‑2026/FY‑2027), a modest constructive signal for near‑term earnings expectations.
• Neutral Sentiment: Elevated retail interest: Zacks/Yahoo highlighted CRSP among most‑searched stocks — this increases volatility potential but is not a directional fundamental driver. Read More.
• Neutral Sentiment: Short‑interest data appears noisy: recent feeds show inconsistent/zero short‑interest figures (likely data artifacts) and do not provide a clear positioning read.
• Negative Sentiment: Convertible senior notes offering: CRISPR priced an upsized $550M convertible notes deal due 2031. Large convertibles can pressure shares (dilution risk, added supply) and were the proximate cause of a sharp intraday sell‑off. Read More.
• Negative Sentiment: Insider selling: CEO Samarth Kulkarni and General Counsel James Kasinger disclosed sales (roughly 9,798 and 2,800 shares) on March 11th; while routine SEC filings often reflect diversification or scheduled plans, investors frequently interpret such sales as negative near‑term signals. Read More.
• Negative Sentiment: Recent price weakness and volatility: media reported multi‑percent intraday declines following the financing announcement, which can trigger momentum selling and keep downward pressure on the stock. Read More.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.